Biofrontera Inc. Files S-1 Registration Statement

TL;DR

<b>Biofrontera Inc. has filed an S-1 registration statement, indicating potential future public offerings of securities.</b>

AI Summary

Biofrontera Inc. (BFRIW) filed a IPO Registration (S-1) with the SEC on March 11, 2024. Biofrontera Inc. has filed an S-1 registration statement with the SEC. The filing is dated March 11, 2024, with the actual filing date as of March 8, 2024. The company is incorporated in Delaware and its fiscal year ends on December 31. Biofrontera Inc. is classified as a non-accelerated filer, smaller reporting company, and emerging growth company. The principal executive offices are located at 120 Presidential Way, Suite 330, Woburn, MA 01801.

Why It Matters

For investors and stakeholders tracking Biofrontera Inc., this filing contains several important signals. This S-1 filing signals Biofrontera's intention to potentially raise capital through the public markets, which could fund its operations, research, and development. As a smaller reporting company and emerging growth company, Biofrontera may have different regulatory and reporting obligations compared to larger, more established firms.

Risk Assessment

Risk Level: low — Biofrontera Inc. shows low risk based on this filing. The filing is a standard S-1 registration statement, which is a preliminary step for potential future securities offerings and does not contain specific financial performance data or operational updates that would indicate immediate risk.

Analyst Insight

Monitor future filings for details on any proposed securities offerings, including the number of shares, pricing, and use of proceeds.

Key Numbers

• 2024-03-11 — Filing Date (As filed with the SEC)
• 2024-03-08 — Conformed Submission Date (Date of submission)
• 1231 — Fiscal Year End (Annual fiscal period end)
• 2834 — SIC Code (Pharmaceutical Preparations)
• 473765675 — IRS Number (Employer Identification No.)
• 333-277811 — SEC File Number (Registration Number)

Key Players & Entities

• Biofrontera Inc. (company) — Registrant name
• Securities and Exchange Commission (regulator) — Filing recipient
• Delaware (company) — State of incorporation
• Woburn, MA (company) — Business address city and state
• Prof. Dr. Hermann Luebbert (person) — Chairman and Chief Executive Officer
• McGuireWoods LLP (company) — Legal counsel
• Stephen E. Older (person) — Esq. at McGuireWoods LLP
• Andrew J. Terjesen (person) — Esq. at McGuireWoods LLP

FAQ

Industry Context

Biofrontera Inc. operates in the pharmaceutical preparations industry, specifically within the biopharmaceutical sector.

Regulatory Implications

The S-1 filing is a standard requirement under the Securities Act of 1933 for companies planning to offer securities to the public.

What Investors Should Do

1. Review the full S-1 filing for details on the proposed securities offering.
2. Track Biofrontera Inc.'s subsequent filings for updates on their capital raising plans.
3. Analyze the company's business strategy and market position in the biopharmaceutical sector.

Year-Over-Year Comparison

This is a new S-1 filing, so there is no prior filing to compare against for changes in financial or operational data.

Key Financial Figures

• $0.001 — Convertible Preferred Stock, par value $0.001 per share (the &ldquo;Series B-1 Prefer
• $1.19 — price per share of our common stock was $1.19. The Selling Stockholders will offer
• $4 billion — market size is estimated to be roughly $4 billion for the three therapy types. Our primar
• $500 million — et, our targeted market is about 11% or $500 million of the total AK market (consisting of t
• $100 million — consisting of the current PDT market at $100 million and the portion of the market attribute
• $400 m — y treatments of more than 14 lesions at $400 million, assuming a tube price of $346).
• $346 — $400 million, assuming a tube price of $346). 6 Our second prescription drug lice

Filing Documents

• forms-1.htm (S-1) — 572KB
• ex107.htm (EX-FILING FEES) — 26KB
• forms-1_001.jpg (GRAPHIC) — 3KB
• 0001493152-24-009456.txt (&nbsp;) — 603KB

RISK FACTORS

RISK FACTORS 8 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 13

USE OF PROCEEDS

USE OF PROCEEDS 14 DIVIDEND POLICY 15

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 16

DESCRIPTION OF SECURITIES AND CERTIFICATE OF INCORPORATION

DESCRIPTION OF SECURITIES AND CERTIFICATE OF INCORPORATION 17 PRIVATE PLACEMENT OF THE PREFERRED STOCK AND WARRANTS 23 SELLING STOCKHOLDERS 24 PLAN OF DISTRIBUTION 25 LEGAL MATTERS 26 EXPERTS 26 WHERE YOU CAN FIND MORE INFORMATION 26 INCORPORATION BY REFERENCE 26 i ABOUT THIS PROSPECTUS We and the Selling Stockholders have not authorized anyone to provide any information or to make any representations other than those contained in this prospectus. We and the Selling Stockholders take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares offered by this prospectus, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside the United States: We and the Selling Stockholders have not done anything that would permit the sale of our common stock being offered by the Selling Stockholders in any jurisdiction where action for that purpose is required, other than in the United relating to, the offering of the shares and the distribution of this prospectus outside the United States . BASIS OF PRESENTATION As used in this prospectus, unless the context otherwise requires, references to &ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; the &ldquo;Company,&rdquo; &ldquo;Biofrontera&rdquo; and similar references refer to Biofrontera Inc. which includes its wholly owned subsidiary Bio-Fri GmbH. References in this prospectus to the &ldquo; Biofrontera Group &rdquo; (a related party) refer to Biofrontera AG and its consolidated subsidiaries, Biofrontera Pharma

Risk Factors

Risk Factors Investing in our common stock involves substantial risk. Our ability to execute our strategy is also subject to certain risks. The risks described under the heading &ldquo;Risk Factors&rdquo; included elsewhere in this prospectus and in our most recent Annual Report on Form 10-K , which is incorporated by reference herein, may cause us not to realize the full benefits of our strengths or may cause us to be unable to successfully execute all or part of our strategy. Some of the most significant challenges and risks include the following: Currently, our sole source of revenue is from sales of products we license from other companies. If we fail to comply with our obligations in the agreements under which we license rights from such third parties, or if the license agreements are terminated for other reasons, we could lose license rights that are important to our business. Certain important patents for our licensed product Ameluz &reg; expired in 2019. Although the process of developing generic topical dermatological products for the first time presents specific challenges that may deter potential generic competitors, generic versions of Ameluz &reg; may enter the market following the recent expiration of these patents. If this happens, we may need to reduce the price of Ameluz &reg; significantly and may lose significant market share. Our business depends substantially on the success of our principal licensed product Ameluz &reg; . If the Ameluz Licensor is unable to successfully obtain and maintain regulatory approvals or reimbursement for Ameluz &reg; for existing and additional indications, our business may be materially harmed. The Ameluz Licensor currently depends on a single unaffiliated contract manufacturer to manufacture Ameluz &reg; and has recently contracted with a second unaffiliated contract manufacturer to begin producing Ameluz &reg; . If the Ameluz Licensor fails to maintain its relationships with these manufacturers or if both

View Full Filing

View this S-1 filing on SEC EDGAR